Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Matthew Budoff MD
@BudoffMd
Great results of Vascepa's effect on physiology, another piece of the puzzle explaining cardiac benefit
https://cardiacwire.com/newsletter/vascepas-coronary-physiology-impact-stress-cvd/
@DLBHATTMD
cardiacwire.com
Vascepa’s Coronary Physiology Impact | Stress & CVD - Cardiac Wire
Amarin's Vascepa improves coronary physiology, exploring stress' CVD impact, and plenty of other cardiology news.
Kiwi, can you contact someone at UW Radiology and find out what the hold up with the release of BRAVE-EPA is due to?
When the f*** are they going to release the BRAVE study results?
Not sure if posted already.
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061986
Canadian Medical & Surgical
@cms_research
·
Nov 9
Practice pearls on #icosapent ethyl. Join the #CV risk reduction discussion with Dr. Lawrence Leiter, Dr. Vineeta Ahooja, @DLBHATTMD, Dr. Grace Chua, Dr. Ron Goldenberg, @RobHegele, and Dr. Subodh Verma on Sat Nov 19. Register for free http://ipe6minconsults.com
Anything from Herper or Feuerstein this morning?
In the PR this morning why didn't they mention anything about the lack of mineral oil in this trial? They should have not only mentioned it, but they should have said something to the effect of "We don't want to hear one more f*cking word about Mineral Oil".
Our favorite MD on lipid management
https://www.medscape.com/viewarticle/973872#vp_4
Not sure if he is talking about Amarin investors pestering him for a comment on the the video posted this morning or not, but here is something from snarky-boy.
Matthew Herper
@matthewherper
·
1h
Subtweet to investors in small biotech companies: If experts are searching for a solution, and your company's product is well-known, they have likely considered it and decided it is not a solution.
Tweeting at me that said solution already exists...is not going to change that.
I did send it to Herper and Harlan Krumholz and asked for any comments. Crickets so far.
Not sure if this has ben posted. Pretty fair. I wonder what Herper and Feurstein would say about this.
https://reachmd.com/programs/cme/clinicians-update-omega-3s-ascvd-risk-reduction/12718/
18 posts today during trading hours. Obviously no one gives a crap about this stock anymore. I get it.
Dr. Deepak L. Bhatt
@DLBHATTMD
Icosapent ethyl's CV mortality shows significant benefit in patients w/ prior #cvMI. @Medscape #JACC https://wb.md/3KnwmyJ
Ted Liamos
@LiamosTed
Replying to
@DLBHATTMD
I've been following your work for a number of years. I'm confused why more Cardiologist haven't adopted Vascepa as a therapy, knowing the results of the Reduce it study. Is it simply that the results are to good to be true, that they don't believe it.
7:18 PM · Apr 26, 2022·Twitter for Android
Dr. Deepak L. Bhatt
@DLBHATTMD
Replying to
@LiamosTed
It always takes time for new therapies to get adopted. Part of it is clinical inertia, part of it is cost/access issues. It took decades for statins to become as widely accepted as they are now.
Ted Liamos
Thank you
Dr. Deepak L. Bhatt
@DLBHATTMD
·
15h
#cardiology #cardiotwitter
@PrakritiGaba
@gabrielsteg
@mmillermd1
@CMichaelGibson
@CBallantyneMD
Quote Tweet
ACC Media Center
@ACCmediacenter
· 16h
Icosapent ethyl's CV mortality shows significant benefit in patients w/ prior #cvMI. @Medscape #JACC https://wb.md/3KnwmyJ
Ted Liamos
@LiamosTed
Replying to
@DLBHATTMD
@PrakritiGaba
and 4 others
I've been following your work for a number of years. I'm confused why more Cardiologist haven't adopted Vascepa as a therapy, knowing the results of the Reduce it study. Is it simply that the results are to good to be true, that they don't believe it.
7:18 PM · Apr 26, 2022·Twitter for Android
1
Like
Dr. Deepak L. Bhatt
@DLBHATTMD
·
1h
Replying to
@LiamosTed
@PrakritiGaba
and 4 others
It always takes time for new therapies to get adopted. Part of it is clinical inertia, part of it is cost/access issues. It took decades for statins to become as widely accepted as they are now.
Ted Liamos
@LiamosTed
·
33m
Thank you
Study mentioned by Dr. Bhatt on Twitter.
https://www.ahajournals.org/doi/full/10.1161/JAHA.121.024999#.Yk2ELSbv7Lw.twitter
Marjac, great job. Question, have you read Hikma’s briefs? If so, any insight you can gleam from them? Did they even address the cropped table?
I don't, but it is an anti-inflammatory.
I was thinking something like this:
$AMRN 's Vascepa has many anti-inflammatory properties. Unfortunately, Cleveland Clinic's very own Dr. Steve Nissen got his butt hurt because his study of a different mixture of EPA and DHA didn't work as well as EPA alone.
I would like to respond to this tweet from the Cleveland Clinic with some snarky comment about Cleveland Clinic's own Dr. Nissen needing to pull his head out of *ss, and prescribe Vascepa for this young lady. Can anyone help me put it in a more PC manner?
Cleveland Clinic Retweeted
ClevelandClinicNews
@CleClinicNews
After Julie hit a crosscourt forehand during a tennis match, she dropped to her knees and fell face-first onto the court.
She never imagined an inflammatory disease was the cause of her sudden cardiac arrest. #LoveYourHeart #GoRedforWomen
https://my.clevelandclinic.org/patient-stories/543-tennis-player-back-on-court-after-cardiac-arrest-from-inflammatory-disease
Never mind. That was from 2020.
Nissen and Cleveland Clinic at it again.
https://consultqd.clevelandclinic.org/strength-results-prompt-questions-about-omega-3-and-cardiovascular-risk/
Any idea when Judge Andrews will rule on the infringement case?
It just sucks that they don't make them say on the prescribing information that this cannot be prescribed for anything other than >500 mg hypertriglicerdemia.
I thought I heard something about a Bhatt v Nissen debate regarding ReduceIt. Did that take place? If so, does anyone have a link to it?
Nope
So, I finally just read the transcript of Karim’s quarterly. First of all I think he is so much more polished than JT. Second, a couple questions. Has any of the doctors on the board seen the new marketing concept? If so, thoughts? If not, why the hell not? Second question, if this is going to work so well, why don’t they roll it out in Europe too?
Response to previous twwet:
May's Financial Options
@MayOptions
Replying to
@KPHeartDoc
@asgmd1
and 5 others
Congrats & good work.
Also congrats to
@amarincorp
@kpthrive
for continuing to investigate the effects of IPE on Cov19, Ath, CVD & Upper Respiratory Tract Infections.
#vacespa #vazkepa can be a game changer
@ATHjournal
@atherosociety
@ESC_Journals
Tweet below:
StonesCapital Retweeted
Andrew P. Ambrosy, MD
@KPHeartDoc
Congrats to the MITIGATE team for finishing recruitment in a first-in-class virtual, EHR-based pragmatic trial of IPE for viral URI prevention in high-risk ASCVD with automated data collection and no F2F encounters!
@asgmd1
@ThidaChanTan
@rvparikh
@MDSolomonMD
@KPDOR
@DLBHATTMD
Herper all over this.
https://www.medpagetoday.com/meetingcoverage/esc/94270
Are they presenting Prepare IT 1 and Prepare IT 2 data on Saturday?
If the results are good to stellar, you can bet your bottom dollar that one, if not all, of those three will have something negative to say about it.
Tweet below. Not sure what the "Dubious prevention arm" means.
Peter Chu
@pcnotpc
$AMRN PREPARE-IT study (NCT04460651 #Vascepa for COVID19, n=4000 Argentina) results due 8/29/21 at ESC. Dubious prevention arm, hopeful on treatment arm. Vascepa fundamentally anti-inflammatory. Serious COVID19 effects due to cytokine storm. PI Rafael Diaz also rpts on colchicine
So the 4/14/20 update showed anticipated 11/30/21 completion, but still recruiting. The 7/23/21 update shows anticipated 1/31/23 completion, but Active, not recruiting. What does the "Active, not recruiting" mean?
Well now I'm confused. The link that TTE forwarded shows January of 2023.
Thank you sir.